Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE.

Autor:	Adamo M; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. Electronic address: mariannaadamo@hotmail.com., Russo G; Department of Biomedicine and Prevention, Cardiology Unit, Policlinico Tor Vergata, University of Rome, Rome, Italy., Pagnesi M; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy., Pancaldi E; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy., Alessandrini H; Department of Cardiology, Asklepios Clinic Sankt Georg, Hamburg, Germany., Andreas M; Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria., Badano LP; Department of Medicine and Surgery, University Milano Bicocca, Milan, Italy; Department of Cardiology, Auxologico IRCCS, Milan, Italy., Braun D; Medical Clinic and Polyclinic I, University Hospital of Munich, Munich, Germany., Connelly KA; Division of Cardiology, Toronto Heart Center, St. Michael's Hospital, Toronto, Ontario, Canada., Denti P; Division of Cardiology, San Raffaele University Hospital, Milan Italy; Department of Cardiac Surgery, San Raffaele University Hospital, Milan Italy., Estevez-Loureiro R; Interventional Cardiology Clinic, University Hospital Alvaro Cunqueiro, Vigo, Spain., Fam N; Division of Cardiology, Toronto Heart Center, St. Michael's Hospital, Toronto, Ontario, Canada., Gavazzoni M; Department of Medicine and Surgery, University Milano Bicocca, Milan, Italy; Department of Cardiology, Auxologico IRCCS, Milan, Italy., Hahn RT; Division of Cardiology, Columbia University Medical Center-NewYork Presbyterian Hospital, New York, New York, USA., Harr C; Department of Cardiology, Asklepios Clinic Sankt Georg, Hamburg, Germany., Hausleiter J; Medical Clinic and Polyclinic I, University Hospital of Munich, Munich, Germany., Himbert D; Division of Cardiology, Bichat Hospital, Paris, France., Kalbacher D; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany., Ho E; Division of Cardiology, Montefiore Medical Center, New York, New York, USA., Latib A; Division of Cardiology, Montefiore Medical Center, New York, New York, USA., Lubos E; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany., Ludwig S; Department of Cardiology, University Heart and Vascular Center, Hamburg, Germany., Lupi L; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy., Lurz P; Heart Center Leipzig at University of Leipzig, Leipzig, Germany., Monivas V; Division of Cardiology, Puerta de Hierro University Hospital, Madrid, Spain., Nickenig G; Heart Center University of Bonn, Bonn, Germany., Pedicino D; Fondazione Policlinico Universitario A Gemelli IRCSS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy., Pedrazzini G; Division of Cardiology, Cardiocentro Ticino Institute, EOC, Lugano, Switzerland; Biomedical Faculty, Università della Svizzera Italiana, Lugano, Switzerland., Pozzoli A; Division of Cardiac Surgery, Cardiocentro Ticino Institute, EOC, Lugano, Switzerland., Marafon DP; Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica Del Sacro Cuore, Rome, Italy., Pastorino R; Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica Del Sacro Cuore, Rome, Italy; Department of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Praz F; Department of Cardiology, Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland., Rodes-Cabau J; Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada., Besler C; Heart Center Leipzig at University of Leipzig, Leipzig, Germany., Schöber AR; Heart Center Leipzig at University of Leipzig, Leipzig, Germany., Schofer J; Department of Medicine and Surgery, University Milano Bicocca, Milan, Italy., Scotti A; Division of Cardiology, Montefiore Medical Center, New York, New York, USA., Piayda K; CardioVascular Center Frankfurt CVC, Frankfurt, Germany., Sievert H; CardioVascular Center Frankfurt CVC, Frankfurt, Germany., Tang GHL; Department of Cardiovascular Surgery, Mount Sinai Health System, New York, New York, USA., Sticchi A; Interventional Cardiology, Humanitas Research Hospital, Rozzano Milanese, Italy., Messika-Zeitoun D; Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada., Thiele H; Heart Center Leipzig at University of Leipzig, Leipzig, Germany., Schlotter F; Heart Center Leipzig at University of Leipzig, Leipzig, Germany., von Bardeleben RS; Division of Cardiology, University Medical Center, Mainz, Germany., Webb J; St. Paul Hospital, Vancouver, British Columbia, Canada., Dreyfus J; Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France., Windecker S; Department of Cardiology, Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland., Leon M; Division of Cardiology, Columbia University Medical Center-NewYork Presbyterian Hospital, New York, New York, USA., Maisano F; Department of Cardiac Surgery, San Raffaele University Hospital, Milan Italy., Metra M; Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria., Taramasso M; HerzZentrum Hirslanden, Zurich, Switzerland.
Jazyk:	angličtina
Zdroj:	JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2024 Apr 08; Vol. 17 (7), pp. 859-870.
DOI:	10.1016/j.jcin.2024.02.013
Abstrakt:	Background: Data on the prognostic role of the TRI-SCORE in patients undergoing transcatheter tricuspid valve intervention (TTVI) are limited. Objectives: The aim of this study was to evaluate the performance of the TRI-SCORE in predicting outcomes of patients undergoing TTVI. Methods: TriValve (Transcatheter Tricuspid Valve Therapies) is a large multicenter multinational registry including patients undergoing TTVI. The TRI-SCORE is a risk model recently proposed to predict in-hospital mortality after tricuspid valve surgery. The TriValve population was stratified based on the TRI-SCORE tertiles. The outcomes of interest were all-cause death and all-cause death or heart failure hospitalization. Procedural complications and changes in NYHA functional class were also reported. Results: Among the 634 patients included, 223 patients (35.2%) had a TRI-SCORE between 0 and 5, 221 (34.8%) had 6 or 7, and 190 (30%) had ≥8 points. Postprocedural blood transfusion, acute kidney injury, new atrial fibrillation, and in-hospital mortality were more frequent in the highest TRI-SCORE tertile. Postprocedure length of stay increased with a TRI-SCORE increase. A TRI-SCORE ≥8 was associated with an increased risk of 30-day all-cause mortality and all-cause mortality and the composite endpoint assessed at a median follow-up of 186 days (OR: 3.00; 95% CI: 1.38-6.55; HR: 2.17; 95% CI: 1.78-4.13; HR: 2.08, 95% CI: 1.57-2.74, respectively) even after adjustment for procedural success and EuroSCORE II or Society of Thoracic Surgeons Predicted Risk of Mortality. The NYHA functional class improved across all TRI-SCORE values. Conclusions: In the TriValve registry, the TRI-SCORE has a suboptimal performance in predicting clinical outcomes. However, a TRISCORE ≥8 is associated with an increased risk of clinical events and a lack of prognostic benefit after successful TTVI. Competing Interests: Funding Support and Author Disclosures Dr Adamo has received speaker honoraria from Abbott. Dr Russo has received a fellowship training grant from the EAPCI sponsored by Edwards Lifesciences. Dr Badano is on the Speaker Bureau of GE Healthcare, Philips Medical Systems, and EsaOte SpA; is currently serving on the Clinical Event Committee of Edwards Lifesciences; and is the director of the echocardiography core laboratory at the Istituto Auxologico Italiano, IRCCS for multiple industry-sponsored trials for which he receives no direct industry compensation. Dr Andreas is a proctor/consultant/speaker for Edwards Lifesciences, Abbott, Medtronic, Boston Scientific, Zoll; and has received institutional research grants from Edwards Lifesciences, Abbott, Medtronic, and LSI. Dr Denti has received speaker honoraria from Abbott and Edwards Lifesciences. Dr Estevez-Loureiro is a consultant for Abbott Vascular, Boston Scientific, and Edwards Lifesciences. Dr Gavazzoni is a proctor for Abbott. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; has stock options with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials for which she receives no direct industry compensation. Dr Nickenig has received honoraria for lectures or advisory boards from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Schofer is a consultant for Edwards Lifesciences. Dr Sievert has received study honoraria to institution, travel expenses, and consulting fees from 4tech Cardio, Abbott, Ablative Solutions, Adona Medical, Akura Medical, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Cardiac Dimensions, Cardiac Success, Cardimed, Cardionovum, Celonova, Contego, Coramaze, Croivalve, CSL Behring LLC, CVRx, Dinova, Edwards Lifesciences, Endobar, Endologix, Endomatic, Esperion Therapeutics, Inc, Hangzhou Nuomao Medtech, Holistick Medical, Intershunt, Intervene, K2, Laminar, Lifetech, Magenta, Maquet Getinge Group, Metavention, Mitralix, Mokita, Neurotronic, NXT Biomedical, Occlutech, Recor, Renal Guard, Shifamed, Terumo, Trisol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, Vivasure Medical, Vvital Biomed, and Whiteswell. Dr Tang has served as a physician proctor for Medtronic; has served as a consultant for Medtronic, Abbott Structural Heart, and NeoChord; has served on the TAVR Advisory Board for Abbott Structural Heart; and has served on the Physician Advisory Board for JenaValve. Dr von Bardeleben has served for trials and principal investigator for Abbott, Edwards Lifesciences, and Medtronic. Dr Windecker has received research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, and V-Wave; has served as an Advisory Board member and/or member of the Steering/Executive Group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis with payments to the institution but no personal payments; and is a member of the Steering/Executive Committee Group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr Maisano is a consultant for Abbott Vascular, Medtronic, Edwards Lifesciences, Perifect, Xeltis, Transseptal Solutions, Magenta, and Cardiovalve; has received grant support from Abbott Vascular, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties from Edwards Lifesciences and 4Tech; and is cofounder/shareholder of Transseptal Solutions, 4Tech, Cardiovalve, Magenta, Perifect, Coregard, and SwissVortex. Dr Metra has received consulting fees from Abbott Vascular, Actelion, Amgen, AstraZeneca, Bayer, Edwards Therapeutics, Livanova, Servier, Vifor Pharma, and WindTree Therapeutics. Dr Taramasso has received consultancy fees from Abbott Vascular, Edwards Lifesciences, 4Tech, Boston Scientific, CoreMedic, Mitraltech, and SwissVortex outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu